BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Analyst Earnings Estimates
NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 270.8M 72.26% | 331.412M 22.38% | 450.712M 36.00% | 621.8M 37.96% | 676.64M 8.82% | 753.98M 11.43% | 876.44M 16.24% | 970.79M 10.77% | 1.054B 8.57% | 1.118B 6.07% | 1.175B 5.10% | |
| EBITDA YoY % growth | -146.96M 16.93% | -100.506M 31.61% | -1.297M 98.71% | 101.74M 7,944.26% | 146.33M 43.83% | 176.46M 20.59% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -148.4M 16.49% | -102.161M 31.16% | -2.543M 97.51% | 109.2M 4,394.14% | 178.18M 63.17% | 231.86M 30.13% | 301.36M 29.97% | 386.27M 28.18% | 455.34M 17.88% | 511.55M 12.34% | 559.52M 9.38% | |
| Operating Margin | -54.80% | -30.83% | -0.56% | 17.56% | 26.33% | 30.75% | 34.38% | 39.79% | 43.20% | 45.76% | 47.62% | |
| EPS YoY % growth | -1.33 -29.13% | -0.99 25.56% | -0.43 56.57% | 0.11 126.24% | 0.49 334.66% | 0.68 37.76% | 1.25 85.66% | 1.58 26.18% | 1.90 20.23% | 2.33 22.59% | 2.54 8.85% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.04 157.56% | 0.05 142.13% | 0.09 | 0.05 -66.00% | 0.06 60.33% | 0.12 111.04% |
| Revenue Q2Q % growth | 159.93M 36.59% | 162.76M 23.74% | 162.37M 11.57% | 161.2M -1.32% | 167.33M 4.63% | 181.23M 11.35% |
| EBITDA Q2Q % growth | 26.903M 211.77% | 29.942M 1,017.90% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 30.425M 295.54% | 31.812M 805.68% | 32.16M 51.51% | 27.607M 8.24% | 33.211M 9.16% | 51.562M 62.08% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 0.15 350.00% | 0.01 | 0.14 | 950.42% |
| Q1 2025 Q2Q % growth | 0.00 100.00% | -0.07 | 0.07 | 100.00% |
| Q4 2024 Q2Q % growth | -0.13 53.57% | -0.06 | -0.07 | -123.60% |
| Q3 2024 Q2Q % growth | -0.07 63.16% | -0.07 | 0.00 | -6.50% |
| Q2 2024 Q2Q % growth | -0.06 75.00% | -0.18 | 0.12 | 66.23% |
| Q1 2024 Q2Q % growth | -0.17 39.29% | -0.22 | 0.05 | 20.98% |
| Q4 2023 Q2Q % growth | -0.28 26.32% | -0.25 | -0.03 | -12.50% |
| Q3 2023 Q2Q % growth | -0.19 17.39% | -0.24 | 0.05 | 20.19% |
| Q2 2023 Q2Q % growth | -0.24 25.00% | -0.23 | -0.01 | -3.06% |
| Q1 2023 Q2Q % growth | -0.28 30.00% | -0.30 | 0.02 | 8.14% |
| Q4 2022 Q2Q % growth | -0.38 -280.00% | -0.17 | -0.21 | -120.09% |
| Q3 2022 Q2Q % growth | -0.23 30.30% | -0.30 | 0.07 | 22.47% |
| Q2 2022 Q2Q % growth | -0.32 -33.33% | -0.35 | 0.03 | 8.62% |
| Q1 2022 Q2Q % growth | -0.40 -11.11% | -0.37 | -0.03 | -7.10% |
| Q4 2021 Q2Q % growth | -0.10 70.59% | -0.31 | 0.21 | 67.82% |
| Q3 2021 Q2Q % growth | -0.33 -26.92% | -0.30 | -0.03 | -9.92% |
| Q2 2021 Q2Q % growth | -0.24 | -0.25 | 0.01 | 2.26% |
| Q1 2021 Q2Q % growth | -0.36 -50.00% | -0.28 | -0.08 | -29.80% |
| Q4 2020 Q2Q % growth | -0.34 -1,600.00% | -0.26 | -0.08 | -32.96% |
| Q3 2020 Q2Q % growth | -0.26 23.53% | -0.26 | 0.00 | 0.16% |
| Q2 2020 Q2Q % growth | -0.24 29.41% | -0.26 | 0.02 | 7.89% |
| Q1 2020 Q2Q % growth | -0.24 14.29% | -0.25 | 0.01 | 3.04% |
| Q4 2019 Q2Q % growth | -0.02 | -0.26 | 0.24 | 92.36% |
| Q3 2019 Q2Q % growth | -0.34 | -0.33 | -0.01 | -4.53% |
| Q2 2019 Q2Q % growth | -0.34 | -0.32 | -0.02 | -7.53% |
| Q1 2019 Q2Q % growth | -0.28 | -0.28 | 0.00 | -0.84% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 163.35M 49.41% | 152.73M | 10.62M | 6.95% |
| Q1 2025 Q2Q % growth | 145.534M 56.89% | 129.4M | 16.134M | 12.47% |
| Q4 2024 Q2Q % growth | 131.534M 40.83% | 132.75M | -1.216M | -0.92% |
| Q3 2024 Q2Q % growth | 117.085M 34.98% | 114.75M | 2.335M | 2.03% |
| Q2 2024 Q2Q % growth | 109.332M 32.54% | 100.29M | 9.042M | 9.02% |
| Q1 2024 Q2Q % growth | 92.761M 34.87% | 87.317M | 5.444M | 6.23% |
| Q4 2023 Q2Q % growth | 93.401M 17.41% | 91.807M | 1.594M | 1.74% |
| Q3 2023 Q2Q % growth | 86.742M 14.39% | 87.673M | -931K | -1.06% |
| Q2 2023 Q2Q % growth | 82.491M 25.88% | 82.606M | -115K | -0.14% |
| Q1 2023 Q2Q % growth | 68.778M 37.78% | 73.111M | -4.333M | -5.93% |
| Q4 2022 Q2Q % growth | 79.55M 68.68% | 77.149M | 2.401M | 3.11% |
| Q3 2022 Q2Q % growth | 75.83M 85.00% | 76.117M | -287K | -0.38% |
| Q2 2022 Q2Q % growth | 65.53M 31.16% | 65.594M | -64K | -0.10% |
| Q1 2022 Q2Q % growth | 49.92M 161.91% | 52.387M | -2.467M | -4.71% |
| Q4 2021 Q2Q % growth | 47.16M 1,073.13% | 50.53M | -3.37M | -6.67% |
| Q3 2021 Q2Q % growth | 40.99M 571.97% | 40.885M | 105K | 0.26% |
| Q2 2021 Q2Q % growth | 49.96M 1,640.77% | 29.245M | 20.715M | 70.83% |
| Q1 2021 Q2Q % growth | 19.06M 295.44% | 9.067M | 9.993M | 110.21% |
| Q4 2020 Q2Q % growth | 4.02M -89.88% | 15.038M | -11.018M | -73.27% |
| Q3 2020 Q2Q % growth | 6.1M 242.70% | 3.677M | 2.423M | 65.90% |
| Q2 2020 Q2Q % growth | 2.87M 97.93% | 2.301M | 569K | 24.73% |
| Q1 2020 Q2Q % growth | 4.82M -18.17% | 4.376M | 444K | 10.15% |
| Q4 2019 Q2Q % growth | 39.73M | 10.074M | 29.656M | 294.38% |
| Q3 2019 Q2Q % growth | 1.78M | 3.024M | -1.244M | -41.14% |
| Q2 2019 Q2Q % growth | 1.45M | 2.06M | -610K | -29.61% |
| Q1 2019 Q2Q % growth | 5.89M | 3.172M | 2.718M | 85.69% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 6.87% | 150.98% | 0% | 243.37% |
| Revenue | 0.14% | 2.74% | -0.39% | 1.54% |